The novel glucagon receptor agonist SAR438544, first in human safety, pharmacokinetic and pharmacodynamic data from a study in healthy volunteers

Publication Authors:

Hompesch, M; Grosjean, P; Morrow, L; Hijazi, Y; Ishibai, M; Teichert, L; Bergmann, K

Poster presented at 53rd European Association for the Study of Diabetes (EASD) Annual Meeting, Lisbon, Portugal, September 2017.

About this Poster:

SAR438544 is a novel synthetic agonist of the glucagon receptor in a stable formulation for subcutaneous (SC) injection to treat hypoglycemia. A first-in-human, randomized, double-blind, glucagon and placebo-controlled, single ascending dose study to evaluate safety, tolerability, PK and PD of SAR438544 was conducted in healthy volunteers.